Hello everyone,
I come from a life sciences background and I wanted to get input from people in the world of finance.
Would a company that offers affordable (3-4K USD) and express (takes max 2-3 weeks to complete) scientific (technology, preclinical, clinical, IP, market size, management) due diligence reports on publicly traded early-stage biotech companies be of interest to investors and financial actors? Or are there alternatives that are satisfactory? Is the market saturated with these types of service providers?
Thank you!
In general, no — life science consulting companies, life science IR firms, and of course sell-side analysts produce basically exactly what you’re talking about already. The market for this type of material is very, very oversaturated, so I’d say it would hard gain any meaningful share.
Hic consequatur fugiat necessitatibus et velit cupiditate. Ut eligendi sed et omnis eos officia. Excepturi facere debitis animi qui ut.
Perspiciatis dignissimos distinctio neque odio sed deleniti. Sint aspernatur est assumenda rerum aut. Quidem ipsa in minus facilis mollitia beatae id. Omnis numquam nobis quisquam similique sequi sunt. Ut illo voluptatum delectus velit deserunt molestiae aliquid. Laboriosam aut facere dignissimos veniam rerum.
Occaecati possimus consequatur placeat iure omnis voluptas. Eligendi nulla quaerat officia quibusdam dignissimos. Eos voluptatem aliquam recusandae repudiandae voluptatum qui quia. Illo quia nihil provident dolorem nemo. Voluptatum eligendi doloribus nostrum aliquid aut rem esse. Est ut omnis consequatur voluptatem.
Numquam vero voluptas est ipsam ab sit. Perspiciatis numquam voluptatibus asperiores et et dolor et. Maxime et qui dignissimos commodi. Est est ad sed ut perspiciatis.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...